Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL29204869 | 0.94 | MEN1 (0.56) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL9298764 | 0.83 | — | — | |
| Tromethamine SCHEMBL680918 | 0.83 | — | — | |
| Tromethamine SCHEMBL28216031 | 0.79 | MEN1 (0.83) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL27944889 | 0.79 | MEN1 (0.83) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL7193959 | 0.79 | MEN1 (0.83) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL975 | 0.79 | — | — | |
| Tromethamine SCHEMBL17484 | 0.79 | MEN1 (1.00) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL3696191 | 0.79 | — | — | |
| Tromethamine SCHEMBL10517974 | 0.76 | MEN1 (0.48) | MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425884-B | De-glu-insulin purifying and preparing process | 北京惠之衡生物科技有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-116425884-A | De-glu-insulin purifying and preparing process | 北京惠之衡生物科技有限公司 | 2023-07-14 | — | — | CN | claimed |
| CN-116355101-A | Preparation method of insulin aspart | 北京惠之衡生物科技有限公司 | 2023-06-30 | — | — | CN | claimed |
| EP-2928903-A1 | OLIGONUCLEOTIDE FORMULATION | Regado Biosciences Inc. (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20140309287-A1 | OLIGONUCLEOTIDE FORMULATION | REGADO BIOSCIENCES, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014089484-A1 | OLIGONUCLEOTIDE FORMULATION | NOVAMEDICA LIMITED LIABILITY COMPANY (RU) | 2014-06-12 | — | — | WO | disclosed |
| EP-1591110-A1 | PERCUTANEOUS ABSORPTION PREPARATION FOR TREATING OPHTHALMIC DISEASE, USE THEREOF AND METHOD FOR MIGRATION OF OPHTHALMIC REMEDY INTO TOPICAL TISSUE IN EYE | Nichiban Company Limited (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309287-A1 | OLIGONUCLEOTIDE FORMULATION | METTL16, RNMT, METTL3 | MEN1 1720/4885LMNA 1490/4885KMT2A 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.